



Announcement No. 14 in 2002/03
April 30, 2003

SIX MONTH REPORT 2002/03 FOR THE CHR. HANSEN GROUP

For the period September 1, 2002 – February 28, 2003 – unaudited

▶ **Chr. Hansen – Food Ingredients**

- ▶ The EBITA margin rose from 9.8% to 12.4%. EBITA increased by 12% to DKK 202 million
- ▶ Sales were unchanged in local currencies
- ▶ Exchange rates dropped 12%, with a corresponding fall in sales to DKK 1,624 million
- ▶ The free sector cash flow amounted to DKK 158 million
- ▶ For the 2002/03 fiscal year, sales are forecast at DKK 3.4–3.5 billion owing to continued falling exchange rates. Nevertheless, the EBITA forecast for 2002/03 is retained, i.e. EBITA is still expected to be higher than the 2001/02 figure, as a result of the increasing EBITA margin

▶ **ALK-Abelló – Allergy Vaccines**

- ▶ Sales increased by 4% to DKK 567 million – organic growth was 6%
- ▶ EBITA for the existing business was DKK 116 million against DKK 118 million in 2001/02
- ▶ Pipeline costs increased to DKK 105 million against DKK 61 million in 2001/02
- ▶ The Phase IIb-III tablet-based grass pollen study was initiated
- ▶ The forecast of an increase in EBITA for the existing business for the 2002/03 fiscal year, compared to 2001/02 is retained – as is the forecast of an increase in pipeline costs of approximately DKK 100 million to approximately DKK 250 million

▶ **Chr. Hansen Group**

- ▶ Sales decreased by 8% to DKK 2,191 million – organic growth was 2%
- ▶ Income from ordinary operations before tax was DKK 107 million compared to DKK 138 million in 2001/02 as a result of the sharply rising pipeline costs in ALK-Abelló
- ▶ Extraordinary items after tax of DKK 40 million relating to a provision in respect of Serbian claim
- ▶ Net interest-bearing debt reduced by DKK 104 million to DKK 2,210 million
- ▶ Net income for the period attributable to Chr. Hansen Holding A/S amounted to minus DKK 1 million against DKK 57 million in 2001/02
- ▶ The forecast for the 2002/03 fiscal year of income from ordinary operations before tax of DKK 140-150 million (excluding provisions for the Serbian claim and costs in preparation of potential independent listing of ALK-Abelló) is retained

Financial review for the six months to February 28, 2003

Chr. Hansen – Ingredients Sector

Income statement, September 1 – February 28						YTD			YTD	
Q2		Q2				02/03			01/02	
01/02	%	02/03	%	DKKm		02/03	%	01/02	%	
885	100	757	100	Net sales		1,624	100	1,833	100	
(568)	64	(462)	61	Cost of goods sold		(979)	60	(1,167)	64	
317	36	295	39	Gross income		645	40	666	36	
(55)	6	(57)	8	Research and development costs		(114)	7	(110)	6	
(189)	22	(163)	22	Sales, marketing and administration expenses		(329)	21	(376)	20	
73	8	75	9	Income from primary operations before amortization of goodwill (EBITA)		202	12	180	10	
(17)	2	(15)	2	Amortization of goodwill		(32)	2	(34)	2	
56	6	60	7	Income from primary operations (EBIT)		170	10	146	8	
64	7	59	8	Depreciation incl. amortization of goodwill charged to the income statement		119	7	128	7	
120	13	119	15	Income from primary operations before depreciation and amortization (EBITDA)		289	17	274	15	

Net sales. Organic growth was 3% in Europe, South America and Asia/Pacific and minus 4% in North America. The combined organic growth rate was 0%.

As exchange rates, especially of USD-related currencies, fell 12% against Danish kroner, total sales fell to DKK 1,624 million from DKK 1,833 in 2001/02.

Cultures reported significant organic growth, driven by the newly introduced Yo-Flex cultures, while a price fall was seen in rennet enzymes and colors caused by a fall in raw material prices.

Management still believes that the low organic growth reflects a temporary stagnation in the ingredients market resulting from inventory adjustments and the negative trend of the global economy. Under these conditions, we have succeeded in improving earnings by way of an increased EBITA margin, partly at the expense of sales growth.

Sales

DKKm	YTD 02/03	YTD 01/02
North America	628	765
Rest of world	996	1,068
Ingredients	1,624	1,833

Europe

Sales in the European region were DKK 730 million in 2001/02 and DKK 746 million in

2002/03. Organic growth was 3%, while falling exchange rates reduced sales by 4%.

North America

Sales in the North American region were down 18% from DKK 765 million to DKK 628 million. Sales fell 4% (organic growth) in USD-terms, while the USD/DKK exchange rate fell 14%. The EBITA margin improved from 6.3% to 7.3%.

Efforts to eliminate low-margin products and low-margin customers have continued, affecting, in particular, organic growth in sales of savory ingredients.

The partnership agreement with US company Foremost Farms announced in the Q1 2002/03 report came into force on December 1, 2002 and has had a positive effect on sales to the pharmaceutical industry.

South America

Sales in the South American region – expressed in Danish kroner – fell 36% from DKK 180 million to DKK 115 million due to the sharp devaluations of the Argentine and Brazilian currencies. The economic downturn caused a substantial fall in the market for industrially produced ingredients, but Chr. Hansen succeeded in retaining its market share in the most important product areas.

Asia/Pacific

Sales in the Asia/Pacific region increased by 7% from DKK 126 million to DKK 135 million. Organic growth was 9%, while falling exchange rates caused sales to fall by 2%. Sales in Asia continue to increase satisfactorily, while sales in Australia

are affected by falling prices of rennet enzymes. An office was opened in Beijing, China.

Gross income fell to DKK 645 million, while the gross margin rose from 36% to 40% as a result of better product and customer mixes.

Capacity costs including R&D costs fell 9% to DKK 443 million as a result of the falling exchange rates.

Income from primary operations before amortization of goodwill (EBITA) increased by 12% to DKK 202 million. The EBITA margin increased from 9.8% to 12.4% as a result of the continued focus on improving profitability.

EBITA

DKKm	YTD 02/03	YTD 01/02
North America	46	48
<i>EBITA % of sales</i>	7.3%	6.3%
Rest of world	156	132
<i>EBITA % of sales</i>	15.7%	12.4%
Ingredients	202	180
<i>EBITA % of sales</i>	12.4%	9.8%

Amortization of goodwill fell DKK 2 million to DKK 32 million.

Income from primary operations (EBIT) increased by 16% to DKK 170 million.

Balance sheet

The invested capital was reduced by DKK 31 million from DKK 3,208 million at the end of 2001/02 to DKK 3,177 million at the end of fiscal Q2 2002/03.

Sector cash flow before financial items

DKKm	YTD 02/03	YTD 01/02
Income from primary operations	170	146
Depreciation and amortization	119	128
Change in working capital, adjustments, etc.	(24)	96
Sector cash flow from operating activities	265	370
Gross investments*	(107)	(116)
Free sector cash flow before financial items	158	254

*) A share of Holding's investments in the sector is included in gross investments.

The free sector cash flow before financial items was an inflow of DKK 158 million compared to DKK 254 million in 2001/02. The free sector cash flow was adversely affected by a planned inventory build-up in cultures in order to meet the expected growth in demand in the second half of the fiscal year.

Outlook for 2002/03

In the annual report for 2001/02, sales were forecast at DKK 3.6-3.7 billion based on the exchange rates prevailing at the end of the fiscal year, including a DKK/USD exchange rate of 7.55.

Due to the falling exchange rates, the sales forecast was adjusted to DKK 3.5-3.6 billion in the Q1 2002/03 report on the basis of the exchange rates prevailing at the end of fiscal Q1, including a DKK/USD exchange rate of 7.48.

Exchange rates continued to fall in fiscal Q2. Applying the exchange rates prevailing at the end of fiscal Q2 (including a DKK/USD exchange rate of 6.88), the sales forecast for the 2002/03 fiscal year is now DKK 3.4-3.5 billion, which is DKK 100 million less than the forecast in the Q1 2002/03 report.

In the second half of the fiscal year, organic sales growth is expected to be approximately 5%, and organic growth for the full year is expected to be 2-3%.

In spite of the reduced sales forecast, the EBITA forecast for 2002/03 is retained, i.e. EBITA is still expected to be higher than the 2001/02 figure as a result of the increasing EBITA margin.

If the above-mentioned assumptions with regard to organic sales growth in the second half of the fiscal year are not realized, sales and EBITA will be adversely affected.

Financial review for the six months to February 28, 2003 ALK-Abelló – Allergy Sector

Income statement, September 1 – February 28						YTD		YTD	
Q2		Q2			02/03		01/02		
01/02	%	02/03	%	DKKm	02/03	%	01/02	%	
252	100	247	100	Net sales	567	100	547	100	
(90)	36	(97)	39	Cost of goods sold	(210)	37	(192)	35	
162	64	150	61	Gross income	357	63	355	65	
(55)	22	(75)	30	Research and development costs	(144)	25	(98)	18	
(97)	38	(99)	40	Sales, marketing and administration expenses	(202)	36	(200)	37	
10	4	(24)	(9)	Income from primary operations before amortization of goodwill (EBITA)	11	2	57	10	
(1)	0	(1)	0	Amortization of goodwill	(1)	0	(2)	0	
9	4	(25)	(9)	Income from primary operations (EBIT)	10	2	55	10	
11	4	11	5	Depreciation incl. amortization of goodwill charged to the income statement	22	4	21	4	
20	8	(14)	(4)	Income from primary operations before depreciation and amortization (EBITDA)	32	6	76	14	

UK study of subcutaneous allergy vaccination

ALK-Abelló has successfully completed the world's largest clinical study of allergy vaccination to date. The double-blind, placebo-controlled, Phase III clinical trial of Alutard[®] SQ *grass pollen* was carried out at 26 allergy clinics in the UK and included 410 adult patients with hay fever caused by grass pollen allergy.

The treatment took place over a period of 30 weeks before and during the 2002 pollen season. Hence, the study focused only on the immediate effect already observed in the first pollen season of the 3-5 year Alutard[®] SQ treatment schedule. The main conclusions are:

Fewer allergy symptoms. As is normal procedure in this type of study, all patients were asked to score their symptoms on a standardized scale. The treatment group reported an average symptom score, which was more than 30% lower than that of the placebo group, indicating a significant reduction of the symptoms in connection with the Alutard[®] SQ treatment.

Less use of other medication. The patients' use of traditional symptom-relieving medication was also registered and converted to a numerical value. The treatment group's average use of other medication was more than 30% lower than that of the placebo group, thus indicating a significant reduction in the use of symptom-relieving medication in connection with the Alutard[®] SQ treatment.

Well tolerated treatment. Allergy vaccination is a treatment based on increasing doses of

standardized natural allergens, which gradually accustoms the patient's immune system to the allergens that normally cause an allergic reaction. The study confirmed the already well-described adverse-event profile. All reactions were controlled using symptom-relieving medication. The study concludes that Alutard[®] SQ is well tolerated.

The results will be used to initiate registration proceedings aiming at a launch of the 3-5 year subcutaneous treatment concept with Alutard[®] SQ *grass pollen* in the UK.

Tablet-based vaccine against grass pollen allergy (sublingual immunotherapy)

ALK-Abelló's Phase IIb-III clinical trial in Europe and Canada of a tablet-based vaccine against grass pollen allergy is progressing according to schedule. By now, more than 90% of the required patients have been enrolled in the study, and most patients are already being treated.

The Phase IIb-III trial assesses safety and efficacy of three different doses of grass pollen allergens compared to placebo. The results of the trial are scheduled to be announced in the first quarter of the 2004 calendar year.

Dr. Steven R. Durham, a leading English allergologist, has completed a meta analysis of 23 smaller studies of sublingual immunotherapy, which concludes that this treatment concept shows high safety and efficacy compared to placebo. Dr. Durham's analysis, which he presented at the annual congress of American allergologists (the American Academy of Allergy,

Asthma & Immunology) in Denver in March, supports ALK-Abelló's concept of tablet-based vaccination.

Cooperation with Schering-Plough

The cooperation with Schering-Plough announced in October 2002 is progressing according to plan.

Restructuring of US activities

The previously announced restructuring of the US activities has been concluded as planned and in line with the budget. Production has been consolidated in New York, and all US customer service, administration and distribution operations are now based in Texas.

Pricing conditions in Germany

In January 2003, the German government passed legislation to introduce a mandatory discount of 6% on all pharmaceutical products sold in Germany in 2003 and 2004. Nevertheless, sales and earnings forecast for ALK-Abelló as a whole is retained.

ALK-Abelló's *in vitro* diagnostics business

ALK-Abelló's *in vitro* diagnostics activities are run in close cooperation with Bayer Diagnostics. Both parties are currently in the process of phasing out the so-called MagicLite product line, whilst phasing in a new and more competitive set of products for Bayer's Advia Centaur *in vitro* diagnostics equipment.

Net sales increased by 4% from DKK 547 million to DKK 567 million. Organic growth was 6%. Sales increased by 6-7% in all regions, except for North America, where organic growth was 4%, but where sales in DKK fell 10% as a result of the falling exchange rates.

Organic growth in sales of allergy vaccines was 6%, consisting of 11% growth in European initial treatments and 4% organic growth in sales of maintenance treatments.

Gross income was DKK 357 million compared to DKK 355 million last year. Gross income was adversely affected by a reduction in inventories, resulting in indirect production costs of DKK 10 million that have been charged to the income statement as cost of goods sold.

Capacity costs increased by DKK 48 million, primarily as a result of increased pipeline costs.

Income from primary operations before amortization of goodwill (EBITA) totaled DKK 11 million compared to DKK 57 million last year.

EBITA for the **existing business** was DKK 116 million compared to DKK 118 million last year. In 2002/03, EBITA for the existing business is affected by the above-mentioned indirect production costs of DKK 10 million, attributable to a DKK 42 million reduction in inventories.

EBITA

DKKm	YTD 02/03	YTD 01/02
Existing business	116	118
EBITA % of sales	20%	22%
Pipeline	(105)	(61)
ALK-Abelló	11	57

Pipeline costs increased from DKK 61 million to DKK 120 million, bringing net pipeline costs to DKK 105 million net of an income of DKK 15 million from Schering-Plough. Net pipeline costs are expected to increase to approximately DKK 250 million for the full year as a result of the Phase IIb-III clinical trial of the grass pollen tablet in Europe and Canada.

Amortization of goodwill was DKK 1 million.

Income from primary operations (EBIT) was DKK 10 million compared to DKK 55 million last year.

Sector cash flow before financial items

DKKm	YTD 02/03	YTD 01/02
Income from primary operations	10	55
Depreciation and amortization	22	21
Change in working capital, adjustments, etc.	34	(10)
Sector cash flow from operating activities	66	66
Gross investments*	(28)	(39)

Free sector cash flow before financial items

38 **27**

*) A share of Holding's investments in the sector is included in gross investments.

The free sector cash flow before financial items was DKK 38 million compared to DKK 27 million in 2001/02 as the effect of reduced inventories and minor investments more than compensate for the fall in income from primary operations.

Outlook for 2002/03

The forecast of organic sales growth of 4-5% is retained for the fiscal year 2002/03. The EBITA margin is expected to continue to improve. Net pipeline costs are expected to increase by approximately DKK 100 million to a total of approximately DKK 250 million as previously announced.

Financial review for the six months to February 28, 2003 – Chr. Hansen Group

Accounting policies

The accounting policies are unchanged from the annual report 2001/02.

Income statement

Income from primary operations has been reviewed above for each segment.

Income from primary operations (EBIT)

Chr. Hansen	DKKm	170
ALK-Abelló	DKKm	10
Holding/eliminations	<u>DKKm</u>	<u>(5)</u>
Chr. Hansen Group	<u>DKKm</u>	<u>175</u>

Holding/eliminations include costs totaling DKK 15 million for the preparation of a potential independent listing of ALK-Abelló. For the full year, this figure is expected to be DKK 15-20 million.

Net financial expenses amounted to DKK 68 million against DKK 69 million last year.

Income before tax amounted to DKK 107 million against DKK 138 million last year.

Tax calculated on income for the period amounts to DKK 46 million, equivalent to 43% of the income. The high tax rate was the result of a substantial part of the amortization of goodwill not being tax deductible and a relatively large proportion of the Group's earnings being derived in countries with a high tax rate.

Extraordinary items after tax were DKK 40 million, cf. note 2, and relate to an arbitration case in Serbia from 1995 that Chr. Hansen subsequently lost, and in February 2003, a French court of appeal made its ruling in the case. The Chr. Hansen Group has decided to appeal the ruling to the Supreme Court of France. We have rejected and we intend to continue to reject the claim as the award is fundamentally inconsistent with the legal order of Denmark and other societies that uphold a rule of law and order as our company was prevented from participating in the underlying surveys by experts in Serbia. Moreover, the composition of the court of arbitration and the appointment of the members of the court suffered from a number of material procedural shortcomings.

The Chr. Hansen Group's net income including minority interests amounted to DKK 21 million against DKK 79 million last year, and net income attributable to Chr. Hansen Holding A/S was minus DKK 1 million against DKK 57 million last year.

Earnings per share amounted to DKK 3.9, excluding extraordinary items, compared to DKK 5.6 last year.

Balance sheet

The invested capital fell by DKK 253 million from 4,329 million at the end of 2001/02 to DKK 4,076 million at the end of fiscal Q2 2002/03.

Equity stood at DKK 1,887 million, equivalent to 35% of total assets.

As a result of the cash inflow generated, net interest-bearing debt was reduced by DKK 104 million from DKK 2,314 million at the end of 2001/02 to DKK 2,210 million at the end of fiscal Q2 2002/03.

The decrease in equity was composed as follows:

Net income for the period	DKKm	(1)
Dividend	DKKm	(20)
Exchange rate adjustments	DKKm	(73)
Hedges of future transactions	<u>DKKm</u>	<u>4</u>
Total decrease in equity	<u>DKKm</u>	<u>(90)</u>

Cash flow	YTD	YTD
DKKm	02/03	01/02
Income from primary operations	175	207
Depreciation, amortization and write-downs	149	156
Change in working capital, adjustments, etc.	(4)	83
Paid interest and tax	(142)	(129)
Cash flow from operating activities	178	317
Investments	(121)	(142)
Free cash flow	57	175

Investments	YTD	YTD
DKKm	02/03	01/02
Gross investments in:		
Chr. Hansen	107	116
ALK-Abelló	28	39
Total gross investments	135	155
Disposals	(14)	(13)
Investments	121	142

The Board of Directors

Karsten Egelund, who served as Vice Chairman of the Board of Chr. Hansen Holding during the last almost 18 months, passed away on March 8, 2003.

The Board of Directors has elected Director Jørgen Worning as new Vice Chairman. Mr. Worning has been a member of the Board of Chr. Hansen Holding A/S since 1990 and is also chairman of the boards of FLS Industries A/S and Bang & Olufsen A/S.

Warrant program for the Corporate Management

The Board of Directors today resolved to establish an incentive program for the Corporate Management by way of a warrant program, see the authorization in article 2.8 of the company's Articles of Association. In accordance with the Board's resolution, 65,000 warrants will be issued to the members of the Corporate Management of Chr. Hansen Holding A/S, comprising 15,000 warrants to the President and CEO and 10,000 warrants to each of the five other members of the Corporate Management.

The program will be based on warrants entitling the holders to subscribe for new B shares in Chr. Hansen Holding A/S against cash payment of the subscription amount. The warrants may be exercised during the period from August 31, 2004 to August 31, 2008. Any warrants remaining unexercised by the end of this period will lapse without any further compensation to the warrant holders. The exercise price is fixed at the average market price of the underlying Chr. Hansen Holding A/S share during the period from September 1, 2002 to March 31, 2003 plus 5%, corresponding to an exercise price of DKK 251.

Applying the Black & Scholes method, the market value of the warrant program of 65,000 warrants amounts to approximately DKK 3 million.

No warrants have been issued to the members of the Board of Directors.

The Chr. Hansen Group's outlook for 2002/03

Assumptions. A stabilization of the global economy and the levels of interest rates and exchange rates prevailing at the end of the second quarter, including a DKK/USD exchange rate of 6.88.

Sales. The sales forecast is DKK 4.4-4.5 billion, equivalent to approximately 3% organic growth.

Income from ordinary operations before tax.

The EBITA forecasts are commented on under each sector. The forecast of Group income from ordinary operations before tax of DKK 140-150 million (excluding provisions for the Serbian claim and costs in preparation of a potential independent listing of ALK-Abelló) is retained.

Financial calendar

May 19, 2003	Capital Market Day
July 3, 2003	Q3 2002/03
Week 47 2003	Annual Report 2002/03
December 17, 2003	Annual General Meeting

Forward-looking statements

This six month report contains forward-looking statements, including forecasts of future sales and income from operations. Such statements are subject to risks and uncertainties as various factors, many of which are beyond the Chr. Hansen Group's control, may cause the actual developments and results to differ materially from the expectations contained in the quarterly report. Factors that might affect such expectations include, among others, overall economic and business conditions, fluctuations in currencies, demand and competitive factors.

This six month report has been translated from Danish into English. However, the Danish text shall be the governing text for all purposes, and in case of any discrepancy the Danish wording shall be applicable.

A meeting of analysts is held today at 3 p.m. CET. This meeting will be webcast and can be followed on www.chr-hansen.com

Hørsholm, April 30, 2003
CHR. HANSEN HOLDING A/S

Sv. Dyrlov Madsen
Chairman

Erik Sørensen
President and CEO

Financial highlights

Chr. Hansen Group

Income statement	DKKm	YTD	YTD
		2002/03	2001/02
Net sales		2,191	2,380
<i>Growth in %</i>		-8%	6%
Cost of goods sold		(1,182)	(1,354)
Gross income		1,009	1,026
Research and development costs		(246)	(197)
Capacity costs, etc.		(554)	(586)
Income from primary operations before amortization of goodwill (EBITA)		209	243
Amortization of goodwill		(34)	(36)
Income from primary operations (EBIT)		175	207
Net financial items incl. result in associated companies before tax		(68)	(69)
Income from ordinary operations before tax		107	138
Tax on ordinary operations		(46)	(59)
Extraordinary items after tax		(40)	-
Minority stockholders' share of the results of subsidiaries		(22)	(22)
Net income (loss) for the period		(1)	57
Income from primary operations before depreciation and amortization (EBITDA)		324	363
Average number of employees		3,503	3,462

Balance sheet	DKKm	Feb 28,	Aug 31,	Feb 28,
		2003	2002	2002
Total assets		5,345	5,388	6,060
Invested capital		4,076	4,329	4,686
Interest-bearing debt - net		2,210	2,314	2,578
Equity		1,887	1,977	2,135
Information on shares				
Shares in 1,000 pcs, DKK 10 each		10,128	10,128	10,128
Cash flow and investments				
Depreciation and amortization		149	306	156
<i>of which amortization of goodwill</i>		34	70	36
Cash flow from primary operations		178	555	317
Investments		(121)	(226)	(142)
Free cash flow		57	329	175
Key figures				
Return on primary operations before amortization of goodwill (EBITA)		9.5	8.0	10.2
Return on primary operations (EBIT)		8.0	6.5	8.7
Equity ratio		35.3	36.7	35.2
Earnings per share before amortization of goodwill (EPSAA) - DKK		7.2	11.7	9.2
Earnings per share (EPS) - DKK		3.9	4.8	5.6
Cash flow per share (CFPS) - DKK		15.4	51.5	29.1
Net asset value per share - DKK		186.3	195.2	210.8

Definitions please see page 16

Income statement, September 1 - February 28

Chr. Hansen Group

Q2 2001/02	Q2 2002/03	DKKm	Note	YTD 2002/03	YTD 2001/02
1,137	1,004	Net sales	1	2,191	2,380
(656)	(554)	Cost of goods sold		(1,182)	(1,354)
481	450	Gross income		1,009	1,026
(104)	(125)	Research and development costs		(246)	(197)
(179)	(176)	Sales and marketing expenses		(360)	(363)
(111)	(92)	Administrative expenses		(209)	(213)
7	11	Other operating income		34	11
(10)	(19)	Other operating costs		(19)	(21)
84	49	Income from primary operations before amortization of goodwill (EBITA)		209	243
(18)	(16)	Amortization of goodwill		(34)	(36)
66	33	Income from primary operations (EBIT)		175	207
-	-	Income before tax from associated companies		-	1
15	1	Interest receivable and other financial income		4	20
(47)	(36)	Interest payable and other financial expenses		(72)	(90)
34	(2)	Income from ordinary operations before tax		107	138
(15)	3	Tax on ordinary operations		(46)	(59)
19	1	Income from ordinary operations		61	79
-	(40)	Extraordinary items after tax	2	(40)	-
19	(39)	Net income for the period including minority interests		21	79
(10)	(8)	Minority stockholders' share of the results of subsidiaries		(22)	(22)
9	(47)	Net income (loss) for the period		(1)	57
		Earnings per share (EPS) excluding extraordinary items - DKK		3.9	5.6

Balance sheet at February 28

Chr. Hansen Group

DKK m	Feb 28, 2003	Aug 31, 2002	Feb 28, 2002
Fixed assets			
Intangible fixed assets			
Goodwill	1,039	1,115	1,222
Other intangible fixed assets	227	247	266
	1,266	1,362	1,488
Tangible fixed assets			
Land and buildings	1,100	1,070	1,173
Plant and machinery	576	581	594
Other fixtures and equipment	141	154	170
Construction in progress	147	190	136
	1,964	1,995	2,073
Financial fixed assets			
Investments in associated companies	3	3	36
Deferred corporate income tax	69	24	134
Securities and receivables	14	12	11
	86	39	181
Total fixed assets	3,316	3,396	3,742
Current assets			
Inventories			
Raw materials and supplies	246	256	311
Work in progress	210	224	257
Finished goods and goods for resale	484	486	553
	940	966	1,121
Receivables			
Trade accounts receivable	650	682	762
Miscellaneous receivables	64	75	62
Tax receivable	25	26	33
Prepayments and deferred charges	63	20	39
	802	803	896
Cash and cash equivalents	287	223	301
Total current assets	2,029	1,992	2,318
Total assets	5,345	5,388	6,060

Balance sheet at February 28

Chr. Hansen Group

DKKm	Note	Feb 28, 2003	Aug 31, 2002	Feb 28, 2002
Equity				
Capital stock	3	101	101	101
Hedges of future transactions		4	(1)	(6)
Other reserves		1,782	1,857	2,040
Proposed dividend		-	20	-
Total equity	4	1,887	1,977	2,135
Minority stockholders				
		60	42	61
Provisions				
Pensions and similar obligations		68	81	70
Deferred corporate income tax		51	64	140
Other obligations		18	7	74
Total provisions		137	152	284
Liabilities				
Long-term liabilities				
Mortgage loans		377	390	402
Other long-term liabilities		1,026	1,574	1,732
		1,403	1,964	2,134
Current liabilities				
Mortgage loans and other long-term liabilities		67	71	65
Bank loans and financial loans		1,040	514	691
Trade accounts payable		264	261	253
Corporate income tax		70	52	81
Miscellaneous payables		367	299	269
Deferred income		50	56	87
		1,858	1,253	1,446
Total liabilities		3,261	3,217	3,580
Total equity, provisions and liabilities		5,345	5,388	6,060

Cash flow statement, September 1 - February 28

Chr. Hansen Group

DKK m	Note	YTD 2002/03	YTD 2001/02
Income from primary operations		175	207
Adjustments	A	151	158
Working capital changes	B	(6)	81
Interest and other financial income received		5	20
Interest and other financial income paid		(81)	(90)
Current income taxes paid		(66)	(59)
Cash flow from operating activities		178	317
Investments - intangible fixed assets		(8)	(3)
Investments - tangible fixed assets		(124)	(156)
Sales of tangible fixed assets		14	13
Change of financial fixed assets		(3)	4
Cash flow from investments		(121)	(142)
Free cash flow		57	175
Dividend paid to Chr. Hansen Holding A/S' stockholders		(20)	(20)
Change in financial liabilities		32	(15)
Minority interests		-	(5)
Cash flow from financing activities		12	(40)
Net cash flow for the period		69	135
Cash and cash equivalents and securities at beginning of period		223	178
Unrealized gain on foreign currency carried as cash and cash equivalents and securities		(5)	(12)
Net cash flow for the period		69	135
Cash and cash equivalents and securities end of period		287	301
A Adjustments			
Depreciation and amortization		149	156
Change in provisions		2	2
		151	158
B Working capital changes			
Inventories		(7)	91
Receivables		34	(7)
Trade accounts payable		7	(34)
Other liabilities		(40)	31
		(6)	81

The cash flow statement has been adjusted to the effect that exchange rate and inflation adjustments in foreign subsidiaries are not included in the statement. As a result, the individual figures in the cash flow statement cannot be obtained directly from the income statement and balance sheet of the Chr. Hansen Group.

Notes to the income statement

Chr. Hansen Group

DKKm	YTD 2002/03	YTD 2001/02
------	----------------	----------------

1 Net sales

Net sales by geographical segments

Denmark	43	39
Europe (excl. Denmark)	1,191	1,180
North America	673	821
Other markets	284	340
Total	<u>2,191</u>	<u>2,380</u>

Net sales by sector

Ingredients Sector	1,624	1,833
Allergy Sector	567	547
Total	<u>2,191</u>	<u>2,380</u>

The above mentioned geographical segment information is distributed according to customer locations.

2 Extraordinary items after tax

Extraordinary items	(60)	-
Tax on extraordinary items	20	-
Total	<u>(40)</u>	-

Extraordinary items relating to a provision made for a claim, raised by a former Serb business partner, including legal costs. In March 2000, a Serbian arbitration court ruled against Chr. Hansen Holding A/S. In February 2003, despite the lack of due process, La Cour d'Appel in Paris allowed enforcement of the arbitration court's award against the Company in France. Chr. Hansen Holding A/S does not currently directly own assets in France. However, it should be expected that attempts will be made to enforce the award in a country in which Chr. Hansen Holding A/S has assets. Chr. Hansen Holding has appealed the ruling to the Supreme Court of France.

Notes to the balance sheet

Chr. Hansen Group

DKKm	Feb 28, 2003	Aug 31, 2002	Feb 28, 2002
3 Capital stock			
Balance at beginning of period	101	101	101
Balance at end of period	101	101	101

The Chr. Hansen Group holds 14,118 own shares.

4 Total equity and minority

Total equity and minority at beginning of period	1,977	2,115	2,115
Net income (loss) for the period	(1)	48	57
Dividend to Chr. Hansen Holding A/S' stockholders	(20)	(20)	(20)
Foreign currency translation adjustment of equity in foreign subsidiary companies at beginning of period	(73)	(162)	(8)
Hedges of future transactions, movements for the period	4	(4)	(9)
Total equity and minority at end of period	1,887	1,977	2,135

Business segments - primary segments

Chr. Hansen Group September 1 - February 28 DKKkm	Ingredients		Allergy		Holding/ eliminations		Chr. Hansen Group	
	YTD	YTD	YTD	YTD	YTD	YTD	YTD	YTD
	2002/03	2001/02	2002/03	2001/02	2002/03	2001/02	2002/03	2001/02

INCOME STATEMENT								
Net sales	1,624	1,833	567	547	-	-	2,191	2,380
Cost of goods sold	(979)	(1,167)	(210)	(192)	7	5	(1,182)	(1,354)
Gross income	645	666	357	355	7	5	1,009	1,026
Research and development costs	(114)	(110)	(144)	(98)	12	11	(246)	(197)
Capacity costs, etc.	(329)	(376)	(202)	(200)	(23)	(10)	(554)	(586)
Income from primary operations before amortization of goodwill (EBITA)	202	180	11	57	(4)	6	209	243
Amortization of goodwill	(32)	(34)	(1)	(2)	(1)	-	(34)	(36)
Income from primary operations (EBIT)	170	146	10	55	(6)	6	175	207

BALANCE SHEET								
Intangible fixed assets	1,133	1,330	133	158	-	-	1,266	1,488
Tangible fixed assets	1,338	1,449	228	221	398	403	1,964	2,073
Financial fixed assets	31	96	47	42	5	7	83	145
Investments in associated companies	-	34	-	-	3	2	3	36
Total fixed assets	2,502	2,909	408	421	406	412	3,316	3,742
Inventories	660	778	280	343	-	-	940	1,121
Receivables	607	702	183	188	12	6	802	896
Cash and cash equivalents	92	107	164	193	31	1	287	301
Total current assets	1,359	1,587	627	724	43	7	2,029	2,318
Total assets	3,861	4,496	1,035	1,145	449	419	5,345	6,060
Total equity and minority	1,869	2,012	80	262	(2)	(78)	1,947	2,196
Provisions	56	188	42	46	39	50	137	284
Long-term liabilities	525	1,218	90	112	788	804	1,403	2,134
Current liabilities	1,411	1,078	823	725	(376)	(357)	1,858	1,446
Total liabilities	1,936	2,296	913	837	412	447	3,261	3,580
Total equity, provisions and liabilities	3,861	4,496	1,035	1,145	449	419	5,345	6,060
INVESTED CAPITAL	3,177	3,598	557	667	342	422	4,076	4,686
INVESTMENTS in fixed assets	87	99	24	36	10	7	121	142

Geographical segments - secondary segments*

Chr. Hansen Group September 1 - February 28 DKKkm	Fixed assets		Current assets		Total assets		Investments fixed assets	
	YTD	YTD	YTD	YTD	YTD	YTD	YTD	YTD
	2002/03	2001/02	2002/03	2001/02	2002/03	2001/02	2002/03	2001/02
Denmark	1,847	1,954	444	402	2,291	2,356	54	57
Europe (excl. Denmark)	546	495	944	1,017	1,490	1,512	49	85
North America	871	1,214	497	674	1,368	1,888	14	(3)
Other markets	52	79	144	225	196	304	4	3
Total	3,316	3,742	2,029	2,318	5,345	6,060	121	142

*) Net sales are specified in note 1. The above geographical segment information has been specified by location of assets.

Definitions

Invested capital	<i>Intangible and tangible fixed assets, inventories and receivables excluding provisions (deferred tax excluded), trade accounts payable, other debt and minorities</i>
Return on primary operations before amortization of goodwill (EBITA)	<i>Income from primary operations before amortization of goodwill x 100/Net sales</i>
Return on primary operations (EBIT)	<i>Income from primary operations x 100/Net sales</i>
Equity ratio	<i>Equity at end of period x 100/Liabilities and equity at end of period</i>
Earnings per share before amortization of goodwill (EPSAA) - DKK	<i>Net income for the period excluding extraordinary items and including amortization of goodwill/Average number of shares</i>
Earnings per share (EPS) - DKK	<i>Net income for the period excluding extraordinary items/Average number of shares</i>
Cash flow per share (CFPS) - DKK	<i>Cash flow from operating activities excluding minority stockholders' share/Average number of shares</i>
Net asset value per share - DKK	<i>Equity at end of period/Number of shares at end of period</i>